PMID- 37285073
OWN - NLM
STAT- MEDLINE
DCOM- 20230720
LR  - 20231116
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 18
IP  - 4
DP  - 2023 Jul
TI  - Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic 
      Renal Cell Carcinoma: A Multicentric UK Real-World Analysis.
PG  - 593-599
LID - 10.1007/s11523-023-00972-8 [doi]
AB  - BACKGROUND: Tivozanib is a licensed as first-line treatment for metastatic renal 
      cell carcinoma (mRCC). OBJECTIVE: To evaluate the outcomes from tivozanib in a 
      real-world mRCC population. PATIENTS AND METHODS: Patients with mRCC commencing 
      first-line tivozanib between March 2017 and May 2019 were identified across four 
      specialist cancer centres in the UK. Data relating to response, overall survival 
      (OS), progression-free survival (PFS) and adverse events (AEs) were collected 
      retrospectively with censoring on 31 December 2020. RESULTS: A total of 113 
      patients were identified: median age was 69 years; 78% had ECOG PS 0-1; 82% had 
      clear cell histology; 66% had previous nephrectomy; International Metastatic RCC 
      Database Consortium (IMDC) score was 22% favourable (F), 52% intermediate (I) and 
      26% poor (P). Twenty-six per cent were switched from another tyrosine kinase 
      inhibitor (TKI) to tivozanib due to toxicity. Median follow-up was 26.6 months 
      with 18% remaining on treatment at data censoring. Median PFS was 8.75 months. 
      Median PFS by IMDC risk group was: F = 23.0 months; I = 10.0 months; P = 3.0 
      months, p value < 0.0001. Median OS was 25.0 months (F = not reached (NR) with 
      72% alive at data cut-off; I = 26.0 months; P = 7.0 months, p value < 0.0001). 
      Seventy-seven per cent had an AE of any grade, and 13% had a grade >/= 3 AE. 
      Eighteen per cent of patients discontinued treatment due to toxicity. No patients 
      who discontinued a prior TKI due to AEs stopped tivozanib due to AEs. 
      CONCLUSIONS: These data suggest comparable activity of tivozanib with the pivotal 
      trial data and other TKIs in a real-world population. Its tolerability positions 
      tivozanib as an attractive first-line option for those unsuitable for combination 
      therapies or unable to tolerate other TKIs.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Heseltine, Jonathan
AU  - Heseltine J
AUID- ORCID: 0000-0001-5204-269X
AD  - The Clatterbridge Cancer Centre, Clatterbridge Road, Bebington, Liverpool, CH63 
      4JY, UK. J.heseltine@nhs.net.
AD  - The University of Liverpool, Liverpool, UK. J.heseltine@nhs.net.
FAU - Allison, Jennifer
AU  - Allison J
AD  - The Christie, Manchester, UK.
FAU - Wong, Sam
AU  - Wong S
AD  - The Royal Marsden, London, UK.
FAU - Prasad, Kellati
AU  - Prasad K
AD  - East Lancashire Teaching Hospitals, Lancashire, UK.
FAU - Oong, Zhu-Chuen
AU  - Oong ZC
AD  - East Lancashire Teaching Hospitals, Lancashire, UK.
FAU - Wong, Helen
AU  - Wong H
AD  - The Clatterbridge Cancer Centre, Clatterbridge Road, Bebington, Liverpool, CH63 
      4JY, UK.
FAU - Law, Andrea
AU  - Law A
AD  - The Clatterbridge Cancer Centre, Clatterbridge Road, Bebington, Liverpool, CH63 
      4JY, UK.
FAU - Charnley, Natalie
AU  - Charnley N
AD  - East Lancashire Teaching Hospitals, Lancashire, UK.
FAU - Parikh, Omi
AU  - Parikh O
AD  - East Lancashire Teaching Hospitals, Lancashire, UK.
FAU - Waddell, Tom
AU  - Waddell T
AD  - The Christie, Manchester, UK.
FAU - Chow, Shien
AU  - Chow S
AD  - The Clatterbridge Cancer Centre, Clatterbridge Road, Bebington, Liverpool, CH63 
      4JY, UK.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230607
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Protein Kinase Inhibitors)
RN  - 172030934T (tivozanib)
SB  - IM
MH  - Aged
MH  - Humans
MH  - *Carcinoma, Renal Cell/pathology
MH  - *Kidney Neoplasms/pathology
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - United Kingdom
EDAT- 2023/06/07 13:10
MHDA- 2023/07/17 06:42
CRDT- 2023/06/07 11:16
PHST- 2023/04/17 00:00 [accepted]
PHST- 2023/07/17 06:42 [medline]
PHST- 2023/06/07 13:10 [pubmed]
PHST- 2023/06/07 11:16 [entrez]
AID - 10.1007/s11523-023-00972-8 [pii]
AID - 10.1007/s11523-023-00972-8 [doi]
PST - ppublish
SO  - Target Oncol. 2023 Jul;18(4):593-599. doi: 10.1007/s11523-023-00972-8. Epub 2023 
      Jun 7.